MXCT Maxcyte Inc

TIDMMXCT TIDMTTM

RNS Number : 3253Y

MaxCyte, Inc.

02 January 2024

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

ROCKVILLE, MD, January 2, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024. In addition, Mr. Masoud now serves as a director on MaxCyte's Board of Directors.

Regulatory

Pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules") and Schedule Two Paragraph (g) of the

AIM Rules, Mr. Maher Issa Masoud, aged 48 does not currently have any other directorship or partnership appointments and has not been a director or a partner of another company within the previous five years. Mr. Masoud also holds 674,200 options over common stock of the Company. There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Mr. Masoud.

MaxCyte Contacts:

 
US IR Adviser                                  +1 415-937-5400 
                                                ir@maxcyte.com 
 Gilmartin Group 
 
 David Deuchler, CFA 
US Media Relations 
 Seismic 
 Valerie Enes 
 
 Nominated Adviser and Joint Corporate Broker  +1 408-497-8568 
 Panmure Gordon 
 Emma Earl / Freddy Crossley 
 Corporate Broking 
 Rupert Dearden                                 +44 (0)20 7886 2500 
UK IR Adviser 
 ICR Consilium                                   +44 (0)203 709 5700 
 Mary-Jane Elliott                               maxcyte@consilium-comms.com 
 Chris Welsh 
 
 
 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT(TM) platform, which is based on our Flow Electroporation(R) technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM), GTx(TM) and VLx (TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUUORRSOUARRR

(END) Dow Jones Newswires

January 02, 2024 02:00 ET (07:00 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024

Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024